{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:02:02Z","timestamp":1784624522684,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81870119"],"award-info":[{"award-number":["81870119"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170153"],"award-info":[{"award-number":["82170153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81720108002"],"award-info":[{"award-number":["81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81700114"],"award-info":[{"award-number":["81700114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Science and Technology Major Project of China","award":["2018ZX09734-007"],"award-info":[{"award-number":["2018ZX09734-007"]}]},{"name":"Jiangsu Provincial Special Program of Medical Science","award":["BE2017751"],"award-info":[{"award-number":["BE2017751"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochem Genet"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10528-025-11284-z","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:12:33Z","timestamp":1763129553000},"page":"5147-5163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute Myeloid Leukemia Patients with High-Risk Karyotypes Benefit from Decitabine in Combination with Modified CAG"],"prefix":"10.1007","volume":"64","author":[{"given":"Ping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"20","key":"11284_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"26","key":"11284_CR2","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","volume":"124","author":"MR Burgess","year":"2014","unstructured":"Burgess MR, Hwang E, Firestone AJ et al (2014) Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood 124(26):3947\u20133955","journal-title":"Blood"},{"issue":"24","key":"11284_CR3","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M et al (2021) Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv 5(24):5565\u20135573","journal-title":"Blood Adv"},{"issue":"7","key":"11284_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.clml.2015.02.017","volume":"15","author":"BW Cooper","year":"2015","unstructured":"Cooper BW, Kindwall-Keller TL, Craig MD et al (2015) A phase I study of midostaurin and Azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk 15(7):428\u2013432e422","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"11284_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, Banks E, Poplin R et al (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43(5):491\u2013498","journal-title":"Nat Genet"},{"issue":"7","key":"11284_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"1","key":"11284_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317","journal-title":"Blood"},{"issue":"12","key":"11284_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136\u20131152","journal-title":"N Engl J Med"},{"issue":"12","key":"11284_CR9","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","volume":"32","author":"H Dohner","year":"2018","unstructured":"Dohner H, Dolnik A, Tang L et al (2018) Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia 32(12):2546\u20132557","journal-title":"Leukemia"},{"issue":"12","key":"11284_CR10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Andrew HW, Frederick RA et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"key":"11284_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.59","volume":"5","author":"HA Hou","year":"2015","unstructured":"Hou HA, Chou WC, Kuo YY et al (2015) TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J 5:e331","journal-title":"Blood Cancer J"},{"issue":"11","key":"11284_CR12","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1080\/10428194.2018.1443328","volume":"59","author":"J Huang","year":"2018","unstructured":"Huang J, Hong M, Zhu Y et al (2018) Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia. Leuk Lymphoma 59(11):2570\u20132579","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"11284_CR13","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488\u20132498","journal-title":"N Engl J Med"},{"issue":"25","key":"11284_CR14","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ et al (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363(25):2424\u20132433","journal-title":"N Engl J Med"},{"issue":"8","key":"11284_CR15","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.18632\/oncotarget.3361","volume":"6","author":"J Li","year":"2015","unstructured":"Li J, Chen Y, Zhu Y et al (2015) Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget 6(8):6448\u20136458","journal-title":"Oncotarget"},{"issue":"14","key":"11284_CR16","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25(14):1754\u20131760","journal-title":"Bioinformatics"},{"issue":"8","key":"11284_CR17","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.26991","volume":"98","author":"AH Matthews","year":"2023","unstructured":"Matthews AH, Perl AE, Luger SM et al (2023) Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol 98(8):1254\u20131264","journal-title":"Am J Hematol"},{"issue":"5","key":"11284_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","volume":"128","author":"KH Metzeler","year":"2016","unstructured":"Metzeler KH, Herold T, Rothenberg-Thurley M et al (2016) Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood 128(5):686\u2013698","journal-title":"Blood"},{"key":"11284_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00395","volume":"10","author":"Y Miao","year":"2019","unstructured":"Miao Y, Zhu HY, Qiao C et al (2019) Pathogenic gene mutations or variants identified by targeted gene sequencing in adults with hemophagocytic lymphohistiocytosis. Front Immunol 10:395","journal-title":"Front Immunol"},{"issue":"1","key":"11284_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2018-11-883454","volume":"133","author":"LC Michaelis","year":"2019","unstructured":"Michaelis LC (2019) Venetoclax in AML: aiming for just right. Blood 133(1):3\u20134","journal-title":"Blood"},{"key":"11284_CR21","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.clml.2015.02.033","volume":"15","author":"MR Muppidi","year":"2015","unstructured":"Muppidi MR, Portwood S, Griffiths EA et al (2015) Decitabine and Sorafenib therapy in FLT-3 ITD-Mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15:S73\u201379","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"11284_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10934-014-9903-7","author":"R Nair","year":"2020","unstructured":"Nair R, Salinas-Illarena A, Baldauf HM (2020) New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia. https:\/\/doi.org\/10.1007\/s10934-014-9903-7","journal-title":"Leukemia"},{"key":"11284_CR23","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events v.5.0 (CTCAE). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 27 Nov 2017"},{"issue":"23","key":"11284_CR24","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221","journal-title":"N Engl J Med"},{"issue":"4","key":"11284_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V et al (2024) Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 99(4):615\u2013624","journal-title":"Am J Hematol"},{"issue":"23","key":"11284_CR26","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","volume":"121","author":"F Ravandi","year":"2013","unstructured":"Ravandi F, Alattar ML, Grunwald MR et al (2013) Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655\u20134662","journal-title":"Blood"},{"key":"11284_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719882822","volume":"10","author":"G Richard-Carpentier","year":"2019","unstructured":"Richard-Carpentier G, DiNardo CD (2019) Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol 10:2040620719882822","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"11284_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson JT, Thorvaldsdottir H, Winckler W et al (2011) Integrative genomics viewer. Nat Biotechnol 29(1):24\u201326","journal-title":"Nat Biotechnol"},{"issue":"9","key":"11284_CR29","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","volume":"119","author":"FG Rucker","year":"2012","unstructured":"Rucker FG, Schlenk RF, Bullinger L et al (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 119(9):2114\u20132121","journal-title":"Blood"},{"issue":"2","key":"11284_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/10428194.2017.1330956","volume":"59","author":"JA Webster","year":"2018","unstructured":"Webster JA, Pratz KW (2018) Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma 59(2):274\u2013287","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"11284_CR31","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA et al (2016) TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023\u20132036","journal-title":"N Engl J Med"},{"issue":"5","key":"11284_CR32","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/ijc.32593","volume":"146","author":"Q Xu","year":"2020","unstructured":"Xu Q, Li Y, Jing Y et al (2020) Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen. Int J Cancer 146(5):1457\u20131467","journal-title":"Int J Cancer"}],"container-title":["Biochemical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-025-11284-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10528-025-11284-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-025-11284-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:08:22Z","timestamp":1784621302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10528-025-11284-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11284"],"URL":"https:\/\/doi.org\/10.1007\/s10528-025-11284-z","relation":{},"ISSN":["0006-2928","1573-4927"],"issn-type":[{"value":"0006-2928","type":"print"},{"value":"1573-4927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and all amendments were approved by the ethics committee of the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital and were conducted per the principles expressed in the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent to participate.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}